Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Rein Therapeutics announced that the first patient has been randomized in the United Kingdom for its Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis. The company has enrolled 16 patients to date across sites in the US, Australia, and the UK, with two additional countries expected to join in coming months.
Key figures
- Drug Name
- LTI-03
- Phase Of Trial
- Phase 2
- Patients enrolled
- 16
- Target enrollment
- 120
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.